Physician profile
Kendall Williams
NPI 1720846652
$852.96
in general payments reported to CMS, 2019-2025
19 companies · $661 in 2025
The $661 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $192 · 2025: $661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $852.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $245.01 | 2024-2025 | |
| Pfizer INC. | $86.03 | 2024-2025 | |
| Novo Nordisk INC | $56.82 | 2024-2025 | Ozempic, Wegovy |
| Exact Sciences Corporation | $52.36 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $48.02 | 2025 | Blenrep, Jemperli |
| Inspire Medical Systems, INC. | $43.70 | 2025 | Inspire |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.73 | 2025 | Caplyta |
| Urogen Pharma, INC. | $33.55 | 2025 | |
| Legend Biotech USA INC. | $32.92 | 2025 | Carvykti |
| Astrazeneca Pharmaceuticals LP | $31.41 | 2025 | Airsupra |
| Lilly USA, LLC | $29.36 | 2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $21.43 | 2024 | Veozah |
| Axsome Therapeutics, INC. | $20.24 | 2025 | Auvelity |
| Regeneron Healthcare Solutions, INC. | $20.05 | 2025 | Lynozyfic |
| Incyte Corporation | $19.56 | 2025 | Monjuvi, Niktimvo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $19.33 | 2025 | Keytruda, Keytruda Qlex |
| Takeda Pharmaceuticals U.S.A., INC. | $19.08 | 2024 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.87 | 2025 | Jardiance |
| Dexcom, INC. | $16.49 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendall Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.